Marinomed Biotech Past Earnings Performance
Past criteria checks 0/6
Marinomed Biotech has been growing earnings at an average annual rate of 17.3%, while the Pharmaceuticals industry saw earnings growing at 9.7% annually. Revenues have been growing at an average rate of 17.6% per year.
Key information
17.3%
Earnings growth rate
23.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 17.6% |
| Return on equity | n/a |
| Net Margin | -74.0% |
| Next Earnings Update | 22 May 2024 |
Revenue & Expenses BreakdownBeta
How Marinomed Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 9 | -7 | 5 | 0 |
| 30 Sep 23 | 11 | -6 | 5 | 0 |
| 30 Jun 23 | 12 | -6 | 5 | 0 |
| 31 Mar 23 | 12 | -7 | 5 | 0 |
| 31 Dec 22 | 11 | -6 | 5 | 0 |
| 30 Sep 22 | 13 | -5 | 5 | 0 |
| 30 Jun 22 | 13 | -5 | 5 | 0 |
| 31 Mar 22 | 12 | -6 | 5 | 0 |
| 31 Dec 21 | 12 | -6 | 5 | 0 |
| 30 Sep 21 | 9 | -8 | 5 | 0 |
| 30 Jun 21 | 9 | -7 | 5 | 0 |
| 31 Mar 21 | 9 | -7 | 5 | 0 |
| 31 Dec 20 | 8 | -6 | 4 | 0 |
| 30 Sep 20 | 8 | -6 | 4 | 0 |
| 30 Jun 20 | 7 | -6 | 4 | 0 |
| 31 Mar 20 | 7 | -6 | 4 | 0 |
| 31 Dec 19 | 7 | -7 | 4 | 0 |
| 30 Sep 19 | 5 | -14 | 4 | 0 |
| 30 Jun 19 | 5 | -15 | 3 | 0 |
| 31 Mar 19 | 5 | -14 | 3 | 0 |
| 31 Dec 18 | 5 | -12 | 3 | 0 |
| 30 Sep 18 | 6 | -4 | 2 | 0 |
| 31 Dec 17 | 5 | -2 | 2 | 0 |
| 31 Dec 16 | 4 | -2 | 2 | 0 |
| 31 Dec 15 | 3 | -1 | 2 | 0 |
Quality Earnings: MARI is currently unprofitable.
Growing Profit Margin: MARI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MARI is unprofitable, but has reduced losses over the past 5 years at a rate of 17.3% per year.
Accelerating Growth: Unable to compare MARI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MARI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.8%).
Return on Equity
High ROE: MARI's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.